Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient

The document reports the first case of frontal fibrosing alopecia (FFA) in an 82-year-old male patient following antiandrogen hormonal therapy for prostate cancer. The patient was treated with oral bicalutamide and subcutaneous goserelin, which led to a recession of the frontotemporal hairline, hypopigmentation, atrophy in areas of alopecia, and loss of axillary and pubic hair. Clinical and histopathological features confirmed the diagnosis of FFA. The article suggests that low serum androgen levels due to the antiandrogen therapy might play a role in the induction of FFA. The authors propose that future studies should measure testosterone serum levels to assess the influence of hormonal therapies on the development of FFA. No conflicts of interest or funding sources were reported for this study.